Li Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li Li has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- An Liu
The Key Laboratory of Developmental Genes and Human Disease, The School of Life Science and Technology, Southeast University, Nanjing, China
1 shared publication C. Jiang Alice
Department of Division of Otolaryngology–Head and Neck Surgery University of Wisconsin Department of Surgery Madison WI
1 shared publicationChen-Chao Chu
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China
1 shared publicationChun-Ying Wu
School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China
1 shared publicationDa Li Yin
Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
1 shared publicationDing-Yuan Ma
Center of Prenatal Diagnosis, Nanjing Maternal and Child Health Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210004, P.R.China
1 shared publication
Latest Publications
- 30 January 2023
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 15 (9) , 1178-1187
A rapid and sensitive LC-ESI-MS/MS method for determining vincristine in micro-volumes of plasma for pediatric cancer patients
Vincristine is a natural vinca alkaloid drug, which is widely used in pediatric cancer treatment with dose-dependent neurotoxicity. Thus far, little is known about the association between neurotoxicity and plasma vincristine concentration, which markedly varies among individuals. Routine therapeutic drug monitoring (TDM) can be seen as a reliable strategy to improve efficacy and reduce side effects. Therefore, a rapid, sensitive, and reproducible method is critical for the clinical implementation of TDM. In this study, micro-volume (50 μL) human plasma samples were prepared by a simple one-step protein precipitation method with acetonitrile. Chromatographic separation of vincristine and its internal standard vincristine-d3 from background noise was achieved on a Kinetex C18 column (2.1 mm × 50 mm, 1.7 μm) with a gradient elution program at a flow rate of 0.3 mL min−1 in 4 min. The mass spectrometric detection was performed in electrospray ionization multiple reaction monitoring mode using the ion transitions of 825.4 → 765.1 for vincristine, and 828.2 → 768.2 for vincristine-d3, respectively. As a result, no matrix effect was observed. The lower limit of quantification was 0.5 ng mL−1 with a precision of 14.6% and an accuracy of 97.4%. The calibration curve was linear from 0.5 to 100 ng mL−1 (r2 > 0.99, n = 8). The intra- and inter-batch precision and accuracy, recovery, and stability of the new method were all within the acceptable criteria. The method was successfully applied to monitor the vincristine concentration for six pediatric cancer patients. Arguably, such proactive TDM of vincristine may be helpful to manage the treatment for these cancer patients.
- 30 January 2023
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 15 (9) , 1178-1187
A rapid and sensitive LC-ESI-MS/MS method for determining vincristine in micro-volumes of plasma for pediatric cancer patients
Vincristine is a natural vinca alkaloid drug, which is widely used in pediatric cancer treatment with dose-dependent neurotoxicity. Thus far, little is known about the association between neurotoxicity and plasma vincristine concentration, which markedly varies among individuals. Routine therapeutic drug monitoring (TDM) can be seen as a reliable strategy to improve efficacy and reduce side effects. Therefore, a rapid, sensitive, and reproducible method is critical for the clinical implementation of TDM. In this study, micro-volume (50 μL) human plasma samples were prepared by a simple one-step protein precipitation method with acetonitrile. Chromatographic separation of vincristine and its internal standard vincristine-d3 from background noise was achieved on a Kinetex C18 column (2.1 mm × 50 mm, 1.7 μm) with a gradient elution program at a flow rate of 0.3 mL min−1 in 4 min. The mass spectrometric detection was performed in electrospray ionization multiple reaction monitoring mode using the ion transitions of 825.4 → 765.1 for vincristine, and 828.2 → 768.2 for vincristine-d3, respectively. As a result, no matrix effect was observed. The lower limit of quantification was 0.5 ng mL−1 with a precision of 14.6% and an accuracy of 97.4%. The calibration curve was linear from 0.5 to 100 ng mL−1 (r2 > 0.99, n = 8). The intra- and inter-batch precision and accuracy, recovery, and stability of the new method were all within the acceptable criteria. The method was successfully applied to monitor the vincristine concentration for six pediatric cancer patients. Arguably, such proactive TDM of vincristine may be helpful to manage the treatment for these cancer patients.
- 19 July 2021
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 146 (17) , 5326-5336
A novel DNA biosensor for the ultrasensitive detection of DNA methyltransferase activity based on a high-density “hot spot” SERS substrate and rolling circle amplification strategy
Herein, a novel biosensor based on a high-density “hot spot” Au@SiO2 array SERS substrate and rolling circle amplification (RCA) strategy for the ultrasensitive detection of CpG methyltransferase (M.SssI) activity was devoloped.
- 19 July 2021
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 146 (17) , 5326-5336
A novel DNA biosensor for the ultrasensitive detection of DNA methyltransferase activity based on a high-density “hot spot” SERS substrate and rolling circle amplification strategy
Herein, a novel biosensor based on a high-density “hot spot” Au@SiO2 array SERS substrate and rolling circle amplification (RCA) strategy for the ultrasensitive detection of CpG methyltransferase (M.SssI) activity was devoloped.
- 1 October 2012
- Published by Wolters Kluwer Health
- Vol. 29 (5) , 510-4
[Prenatal diagnosis of two fetuses with de novo small supernumerary markers by single nucleotide polymorphism array based comparative genomic hybridization].
To explore the origins of small de novo mosaic supernumerary marker chromosomes (mars) in two fetuses, and to assess the feasibility of single nucleotide polymorphism array-based comparative genomic hybridization (SNP-array CGH) for prenatal molecular cytogenetic diagnosis. Two fetuses with de novo were identified. SNP-array marker chromosomes was applied to define the location and range of marker chromosomes. The karyotype of fetus I was determined to be 47,XX,+ mar[23]/46,XX[16], and that of fetus II was 47,XX,+ mar. Multiplex ligation-dependent probe amplification (MLPA) was applied to verify the genomic imbalance found in fetus II. The karyotypes of parents were normal in both families. SNP-array CGH has indicated a 8.3 Mb duplication at 9p21.1-p21.3 in fetus I, and a 10.8 Mb duplication at 15q11.2-q13.3 in fetus II. MLPA has also confirmed a 15q terminal duplication in fetus II. Above cases have illustrated that SNP-array CGH is a rapid, powerful and sensitive technique which may be used for identify the origins of marker chromosomes in prenatal diagnosis.
- 1 October 2012
- Published by Wolters Kluwer Health
- Vol. 29 (5) , 510-4
[Prenatal diagnosis of two fetuses with de novo small supernumerary markers by single nucleotide polymorphism array based comparative genomic hybridization].
To explore the origins of small de novo mosaic supernumerary marker chromosomes (mars) in two fetuses, and to assess the feasibility of single nucleotide polymorphism array-based comparative genomic hybridization (SNP-array CGH) for prenatal molecular cytogenetic diagnosis. Two fetuses with de novo were identified. SNP-array marker chromosomes was applied to define the location and range of marker chromosomes. The karyotype of fetus I was determined to be 47,XX,+ mar[23]/46,XX[16], and that of fetus II was 47,XX,+ mar. Multiplex ligation-dependent probe amplification (MLPA) was applied to verify the genomic imbalance found in fetus II. The karyotypes of parents were normal in both families. SNP-array CGH has indicated a 8.3 Mb duplication at 9p21.1-p21.3 in fetus I, and a 10.8 Mb duplication at 15q11.2-q13.3 in fetus II. MLPA has also confirmed a 15q terminal duplication in fetus II. Above cases have illustrated that SNP-array CGH is a rapid, powerful and sensitive technique which may be used for identify the origins of marker chromosomes in prenatal diagnosis.
- 1 October 2012
- Published by Elsevier in Chinese Chemical Letters
- Vol. 23 (10) , 1197-1200
ECD spectrometric methods for detecting the enantioselective enzymatic hydrolysis of racemic 3-acetoxy-4-phenyl-β-lactam
- 1 October 2012
- Published by Elsevier in Chinese Chemical Letters
- Vol. 23 (10) , 1197-1200
ECD spectrometric methods for detecting the enantioselective enzymatic hydrolysis of racemic 3-acetoxy-4-phenyl-β-lactam
- 1 October 2007
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 137 (4) , 659-664
The characteristics of Hep‐2 cell with multiple drug resistance induced by Taxol
Objectives To investigate the characteristics of Hep-2 cell with multidrug resistance (MDR) induced by Taxol. Study Design Hep-2 cells were exposed in stepwise ...
- 1 October 2007
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 137 (4) , 659-664
The characteristics of Hep‐2 cell with multiple drug resistance induced by Taxol
Objectives To investigate the characteristics of Hep-2 cell with multidrug resistance (MDR) induced by Taxol. Study Design Hep-2 cells were exposed in stepwise ...